Managing cardiovascular risk factors: Trial evidence in women

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 20, Issue 6, 2010, Pages 445-450

  Hsia, J ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Coronary heart disease; Prevention; Risk factor; Women

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN;

BLOOD; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DIABETIC ANGIOPATHY; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MALE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; SMOKING; WOMEN'S HEALTH;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SMOKING; WOMEN'S HEALTH;

EID: 77954953628     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2010.01.010     Document Type: Review

References (35)

1. Kotseva K., Wood D., De Backer G., De Bacquer D., Pyorala K., Keil U., et al. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II and III surveys in eight European countries. Lancet 2009, 373:929-940.
2. Ong K.L., Cheung B.M.Y., Man Y.B., Lau C.P., Lam K.S.L. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007, 49:69-75.
3. Ford E.S., Li C., Pearson W.S., Zhao G., Mokdad A.H. Trends in hypercholesterolemia, treatment and control among United States adults. Int J Cardiol 2008, 10.1016/j.ijcard.2008.11.033.
4. Ong K.L., Cheung B.M.Y., Wong L.Y.F., Wat N.M.S., Tan K.C.B., Lam K.S.L. Prevalence, treatment, and control of diagnosed diabetes in the U.S. National health and Nutrition Examination survey 1999-2004. Ann Epidemiol 2008, 18:222-229.
5. Turnbull F., Woodward M., Neal B., Barzi F., Ninomiya T., Chalmers J., et al. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. Eur Heart J 2008, 29:2669-2680.
6. Expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Executive summary of the third report of the National cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult treatment panel III). JAMA 2001, 285:2486-2497.
7. Cholesterol Treatment Trialists' Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomized trials of statins. Lancet 2005, 366:1267-1278.
8. Rosenberg H., Allard D. Women and statin use: a women's health advocacy perspective. Scand Cardiovasc J 2008, 42:268-273.
9. Kakafika A.I., Athyros V.G., Tziomalos K., Karagioannis A., Mikhailidis D.P. Primary and secondary coronary heart disease prevention using statins: is targeting Adam or Eve equally effective?. Expert Opin Pharmacother 2008, 9:1437-1440.
10. Miettinen T.A., Pyorala K., Olsson A.G., Musliner T.A., Cook T.J., Faegerman O., et al. Cholesterol lowering therapy in women and elderly patients with myocardial infarction or angina pectoris. Findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 1997, 96:4211-4219.
11. Lewis S.J., Sacks S.M., Mitchell J.S., East C., Glasser S., Kell S., et al. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the Cholesterol and Recurrent Events (CARE) trial. J Am Coll Cardiol 1998, 32:140-146.
12. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002, 360:7-22. Heart Protection Study Collaborative Group.
13. Hague W., Forder P., Simes J., Hunt D., Tonkin A. LIPID investigators. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study. Am Heart J 2003, 145:643-651.
14. Shepherd J., Blauw G.J., Murphy B.M., Bollen E.L.E.M., Buckley B.M., Cobbe S.M., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002, 360:1623-1630.
15. Sever P.S., Dahlof B., Poulter N.R., Wedel H., Beevers G., Caulfield M., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 2003, 361:1149-1158.
16. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995, 333:1301-1307.
17. Clearfield M., Downs J.R., Weis S., Whitney E.J., Kruyer W., Shapiro D.R., et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women. J Wom Health Gend Base Med 2001, 10:971-981.
18. Ridker P.M., Danielson E.D., Fonseca F.A.H., Genest J., Gotto A.M., Kastelein J.J.P., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207.
19. Ridker P.M., MacFadyen J.G., Fonseca F.A.H., Genest J., Gotto A.M., Kastelein J.J.P., et al. Number needed to treat with rosuvastatin to prevent cardiovascular events and death among men and women with low LDL cholesterol and elevated hsCRP: the JUPITER trial. Circ Cardiovasc Qual Outcomes 2009, 2:616-623.
20. Kumana C.R., Cheung B.M.Y., Lauder I.J. Gauging the impact of statins using number needed to treat. JAMA 1999, 282:1899-1901.
21. Wiysonge CS, Bradley H, Mayosi BM, Maroney R, Mbewu A, Opie LH, Volmink J. Beta-blockers for hypertension. Cochrane Database Systematic Reviews, Issue 1. Art. No :CD002003.DOI:1. 1002/14651858. CD002003.pub2; 2007.
22. Berger J.S., Roncaglioni M.C., Avanzini F., Pangrazzi I., Tognoni G., Brown D.L. Aspirin for the primary prevention of cardiovascular events in women and men. A sex-specific meta-analysis of randomized controlled trials. JAMA 2006, 295:306-313.
23. Alsheikh-Ali A.A., Trikalinos T.A., Kent D.M., Karas R.H. Statins, low-density lipoprotein cholesterol, and risk of cancer. J Am Coll Cardiol 2008, 52:1141-1147.
24. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996, 335:1001-1009.
25. Skyler J.S., Howard B.V., Bergenstal R., Kirkman M.S., Bonow R.O., Kosiborod M., et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials. J Am Coll Cardiol 2009, 53:298-304.
26. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559. Action to Control Cardiovascular Risk in Diabetes Study Group.
27. Gaede P., Lund-Anderson H., Parving H.-H., Pederson O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358:580-591.
28. American Diabetes Association Executive summary: standards of medical care in diabetes - 2010. Diabetes Care 2010, 33(Suppl. 1):S11-S61.
29. Volpp K.G., Troxel A.B., Pauly M.V., Glick H.A., Piug A., Asch D.A., et al. A randomized, controlled trial of financial incentives for smoking cessation. N Engl J Med 2009, 360:699-709.
30. Gonzalez D., Rennard S.I., Nides M., Oncken C., Azoulay S., Billing C.B., et al. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation. A randomized controlled trial. JAMA 2006, 296:47-55.
31. http://www.reynoldsriskscore.org.
32. Pearson T.A., Mensah G.A., Alexander R.W., Anderson J.L., Cannon R.O., Criqui M., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107:499-511.
33. Myers G.L., Christenson R.H., Cushman M., Ballantyne C.M., Cooper G.R., Pfeiffer C.M., et al. National Academy of clinical Biochemistry Laboratory Medicine practice guidelines: emerging biomarkers for primary prevention of cardiovascular disease. Clin Chem 2009, 55:378-384.
34. Ridker P.M., Danielson E., Fonseca F.A.H., Genest J., Gotto A.M., Kastelein J.J.P., et al. Reduction in C-reactive protein and LDL vholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009, 373:1175-1182.
35. Ford E.S., Giles W.H., Mokdad A.H., Myers G.L. Distribution and correlates of C-reactive protein concentrations among adult US women. Clin Chem 2004, 50:574-581.